Pierantonio Menna
Università Campus Bio-Medico
63 Papers
773 Citations
Pierantonio Menna is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Cardiotoxicity & Anthracycline. The author has an hindex of 22, co-authored 51 publications. Previous affiliations of Pierantonio Menna include University of Chieti-Pescara.
Chat about Author
Papers
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Cardiotoxicity of antitumor drugs.
TL;DR: Mechanism-based considerations and retrospective analyses of clinical trials now form the basis for a new classification of cardiotoxicity, type I for anthracyclines vs type II for Trastuzumab, which may serve a template to accommodate other paradigms ofCardiotoxicity induced by new drugs and combination therapies.
164
Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.
Giorgio Minotti,Stefania Recalcati,Pierantonio Menna,Emanuela Salvatorelli,Gianfranca Corna,Gaetano Cairo +5 more
TL;DR: Experimental evidence suggesting that Doxorubicin (DOX) and other anthracyclines can act at an intracellular level, perhaps by altering the function of iron regulatory proteins (IRP) that serve to maintain low molecular weight iron pool within physiologic concentrations is reviewed.
135
Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION
Emanuela Salvatorelli,Simone Guarnieri,Pierantonio Menna,Giovanni Liberi,Antonio M. Calafiore,Maria A. Mariggiò,Alvaro Mordente,Luca Gianni,Giorgio Minotti +8 more
TL;DR: Vesicular sequestration and impaired efficiency of electron addition have separate roles in determining a defective bioactivation of epirubicin to ROS or secondary alcohol metabolites in the human heart.
93
Pharmacological Foundations of Cardio-Oncology
TL;DR: The lifetime risk of cardiotoxicity from antitumor drugs needs to be reconciled with the identification of long-lasting pharmacological signatures that overlap with comorbidities, and research on targeted drugs should be reshaped to appreciate that the terminal ballistics of new "magic bullets" might involve cardiomyocytes as innocent bystanders.
83